Format

Send to

Choose Destination
See comment in PubMed Commons below
Rheum Dis Clin North Am. 2011 Aug;37(3):387-400, vi. doi: 10.1016/j.rdc.2011.08.001.

Long-term safety concerns of antiresorptive therapy.

Author information

1
Health Services/Comparative Effectiveness Research Training Program, Department of Epidemiology, University of Alabama at Birmingham, 1665 University Boulevard, RPHB 517B, Birmingham, AL 35294, USA.

Abstract

Bisphosphonates reduce the risk of major osteoporotic fractures and are the most commonly used medications for the prevention and treatment of osteoporosis. Although these medications are well tolerated and safe during large-scale clinical trials, several rare and serious adverse events are suspected to be associated with long-term bisphosphonate use. These adverse events include osteonecrosis of the jaw, atypical fractures, and esophageal cancer. This review summarizes studies examining the association between bisphosphonate use and these adverse outcomes, with a focus on large case series and controlled epidemiologic studies.

PMID:
22023898
PMCID:
PMC4420195
DOI:
10.1016/j.rdc.2011.08.001
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center